SLC5A2 and diabetic cardiomyopathy: EMPA, a selective inhibitor of SGLT2, has been reported to exert cardioprotective effects in several cardiovascular diseases, including diabetic cardiomyopathy (DCM) (Li et al., 2019), myocardial infarction (Andreadou et al., 2017), cardiorenal syndrome (Yang et al., 2019), and doxorubicin-induced heart failure (Oh et al., 2019).